6th February 2023

The University of Aberdeen Epidemiology Group is collaborating with the British Society for Antimicrobial Chemotherapy (BSAC) to develop the first UK Antimicrobial Registry (UKAR). In this post, the group provide an update on how the project is progressing, and explain how your hospital can get involved in this exciting project…

The UK Antimicrobial Registry (UKAR) Study team are “all systems go” preparing for the launch of our pilot sites at the University Hospitals of Leicester NHS Trust, Manchester University NHS Foundation Trust, Queen Elizabeth University Hospital Glasgow and Aberdeen Royal Infirmary.

The UKAR study, which is a collaboration between The University of Aberdeen Epidemiology group and BSAC, aims to provide answers to some very important questions:

  • How widely are the antimicrobials included in the UKAR study being used across the UK?
  • Which patient groups are being prescribed the drugs included in the study?
  • Which infection types are being treated and why are these drugs being selected for use?
  • How safe and effective are these antimicrobials in real-world use?

Drugs on the UKAR list, such as Cefiderocol and Ceftazidime/Avibactam, were designed use in drug-resistant infections and are part of the NICE de-linkage initiative, which is intended to increase investment in new antimicrobials. At the recent BSAC Winter Conference Dr Luke Moore discussed the role that the UK Antimicrobial Registry will play in this initiative.

A major focus of the Aberdeen team just now is getting our pilot sites are up and running. Once underway, we will continue to work with Antimicrobial Teams and research nurses at these sites as they collect relevant data from the notes of patients enrolled in the study. Data collection will include information about the cause and site of the infection, the drugs used to combat these infections, the outcomes of treatment with the study drugs and any adverse effects or relapse of infection. The pilot phase will last 3 months, then the process and results  will be evaluated, and we will use the lessons learned to revise our approach as required.

The study will then be rolled out to hospitals across the UK, with recruitment of participants set to continue from 2023 through to summer 2026. We have already received expressions of interest from several hospitals and would encourage any clinicians using one or more of the study drugs to get in touch to find out more about join this exciting initiative.

If you would like to learn more about the UKAR Study, please don’t hesitate to contact the UKAR Study Coordination Team on ukar@abdn.ac.uk, visit the UKAR study website or access the UKAR Expression of Interest Form. It would be great to talk to you about getting your hospital on board.

GP? Pharmacist? Researcher? Social Scientist? Whatever field you work in, if you’re committed to fighting infection then we want you to join us as a BSAC Member.
Become a member

Having trouble finding what you're after?

Top